Phase II Study of Sunitinib in Tumors With c-KIT Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V.

Autor: Gien LT; Odette Cancer Centre-Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Song Z; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Poklepovic A; Virginia Commonwealth University/Massey Cancer Center, Richmond, VA., Collisson EA; Fred Hutchinson Cancer Center, Seattle, WA., Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Gray RJ; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., Wang V; Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA., McShane LM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Rubinstein LV; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Patton DR; Center for Biomedical Informatics & Information Technology, National Cancer Institute, Bethesda, MD., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD.; Deceased., Hamilton SR; City of Hope National Medical Center, Duarte, CA., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Conley BA; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Arteaga CL; UT Southwestern Simmons Comprehensive Cancer Center, Dallas, TX., Harris LN; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., O'Dwyer PJ; University of Pennsylvania, Philadelphia, PA., Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Flaherty KT; Massachusetts General Hospital Cancer Center; Boston, MA.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2024 Dec; Vol. 8, pp. e2400514. Date of Electronic Publication: 2024 Dec 12.

Cosmic-Ray Radiation Effects on Ibuprofen Tablet Formulation Inside and Outside of the International Space Station.

Autor: Tran QD; School of Chemical Engineering, The University of Adelaide, Adelaide, South Australia, 5005, Australia.; Andy Thomas Centre for Space Resources, The University of Adelaide, Adelaide, South Australia, 5005, Australia., Spooner N; School of Physical Sciences, The University of Adelaide, Adelaide, South Australia, 5005, Australia., Geoghehan S; Department of Radiation Oncology, Central Adelaide Local Health Network, Adelaide, 5000, Australia., Thavarajah SR; School of Chemical Engineering, The University of Adelaide, Adelaide, South Australia, 5005, Australia., Rahman S; School of Chemical Engineering, The University of Adelaide, Adelaide, South Australia, 5005, Australia., Tran NN; School of Chemical Engineering, The University of Adelaide, Adelaide, South Australia, 5005, Australia., Williams PM; School of Pharmacy, Boots Science Building, University of Nottingham, Nottingham, NG7 2RD, United Kingdom., Jarquin SM; School of Pharmacy, Boots Science Building, University of Nottingham, Nottingham, NG7 2RD, United Kingdom., Kim DH; School of Pharmacy, Boots Science Building, University of Nottingham, Nottingham, NG7 2RD, United Kingdom., Davey K; School of Chemical Engineering, The University of Adelaide, Adelaide, South Australia, 5005, Australia., Buell J; Aegis Aerospace, Inc., Houston, Texas, 77598, USA., Shumbera M; Aegis Aerospace, Inc., Houston, Texas, 77598, USA., Gittleman M; Aegis Aerospace, Inc., Houston, Texas, 77598, USA., Clements T; Space Tango, Lexington, 40505, USA., Stoudemire J; Space Tango, Lexington, 40505, USA.; Axiom Space, Houston, 77058, USA., Fisk I; International Flavour Research Centre, Division of Food, Nutrition and Dietetics, University of Nottingham, Nottingham, LE12 5RD, United Kingdom.; International Flavour Research Centre, School of Agriculture, Food and Wine and Waite Research Institute, The University of Adelaide, Adelaide, South Australia, 5064, Australia., Hessel V; School of Chemical Engineering, The University of Adelaide, Adelaide, South Australia, 5005, Australia.; Andy Thomas Centre for Space Resources, The University of Adelaide, Adelaide, South Australia, 5005, Australia.; School of Engineering, University of Warwick, Coventry, CV4 7AL, United Kingdom.

Publikováno v: Advanced healthcare materials [Adv Healthc Mater] 2024 Oct 23, pp. e2402361. Date of Electronic Publication: 2024 Oct 23.

Resource requirements to accelerate clinical applications of next-generation sequencing and radiomics: workshop commentary and review.

Autor: Harris L; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Shankar LK; Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Hildebrandt C; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Rubinstein WS; Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Langlais K; Office of In Vitro Diagnostics (OHT7), Office of Product Evaluation and Quality, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA., Rodriguez H; Office of Cancer Clinical Proteomics Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Berger A; Division of Clinical and Healthcare Research Policy, Office of Science Policy, National Institutes of Health, Bethesda, MD, USA., Freymann J; Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Huang EP; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Williams PM; Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zenklusen JC; The Cancer Genome Atlas, Center for Cancer Genomics, Office of the Director, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Ochs R; Office of Health Technology 8, Office of Product Evaluation and Quality, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA., Tezak Z; Office of In Vitro Diagnostics (OHT7), Office of Product Evaluation and Quality, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA., Sahiner B; Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA.

Publikováno v: Journal of the National Cancer Institute [J Natl Cancer Inst] 2024 Oct 01; Vol. 116 (10), pp. 1562-1570.

Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D.

Autor: Laetsch TW; Children's Hospital of Philadelphia/University of Pennsylvania, Philadelphia, PA., Ludwig K; University of Texas Southwestern, Dallas, TX., Williams PM; Frederick National Laboratory for Cancer Research, Frederick, MD., Roy-Chowdhuri S; University of Texas MD Anderson Cancer Center, Houston, TX., Patton DR; Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD., Coffey B; Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD., Reid JM; Mayo Clinic Comprehensive Cancer Center, Rochester, MN., Piao J; Keck School of Medicine, University of Southern California, Los Angeles, CA., Saguilig L; Children's Oncology Group Statistical Center, Monrovia, CA., Alonzo TA; Keck School of Medicine, University of Southern California, Los Angeles, CA., Berg SL; Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX., Mhlanga J; Washington University School of Medicine, St Louis, MO., Fox E; St Jude Children's Research Hospital, Memphis, TN., Weigel BJ; University of Minnesota, Minneapolis, MN., Hawkins DS; Seattle Children's Hospital and University of Washington, Seattle, WA., Mooney MM; Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD., Takebe N; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Janeway KA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA., Seibel NL; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD., Parsons DW; Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX.

Publikováno v: JCO precision oncology [JCO Precis Oncol] 2024 Sep; Vol. 8, pp. e2400258.

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.

Autor: Nelson MV; Children's National Hospital, Washington, DC 20010, United States., Kim A; Children's National Hospital, Washington, DC 20010, United States., Williams PM; Frederick National Laboratory for Cancer Research, Frederick MD 21701, United States., Roy-Chowdhuri S; University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Patton DR; Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD 20892, United States., Coffey BD; Center for Biomedical Informatics and Information Technology, NCI, NIH, Bethesda, MD 20892, United States., Reid JM; Mayo Clinic, Rochester, MN 55905, United States., Piao J; Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, United States., Saguilig L; Children's Oncology Group Statistical Center, Monrovia, CA 91016, United States., Alonzo TA; Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, United States., Berg SL; Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX 77030, United States., Ramirez NC; Biopathology Center, Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, United States., Jaju A; Ann and Robert H. Lurie Children's Hospital, Chicago, IL 60611, United States., Fox E; St Jude Children's Research Hospital, Memphis, TN 38105, United States., Weigel BJ; University of Minnesota/Masonic Cancer Center, Minneapolis, MD 55455, United States., Hawkins DS; Seattle Children's Hospital and University of Washington, Seattle, WA 98105, United States., Mooney MM; Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, United States., Takebe N; Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, United States., Tricoli JV; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, United States., Janeway KA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States., Seibel NL; Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, United States., Parsons DW; Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX 77030, United States.

Publikováno v: The oncologist [Oncologist] 2024 Aug 05; Vol. 29 (8), pp. 723-e1093.